Cargando…

Downregulation of miR-335 exhibited an oncogenic effect via promoting KDM3A/YAP1 networks in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cancer affecting many people worldwide. Although the 5-year survival rate is 65% in localized disease, after metastasis, the survival rate is <10%. Emerging evidence has shown that microRNAs (miRNAs) play a crucial regulator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenqiang, Liu, Ruiyu, Zhang, Lin, Wang, Chao, Dong, Ziyan, Feng, Jiasheng, Luo, Mayao, Zhang, Yifan, Xu, Zhuofan, Lv, Shidong, Wei, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113937/ https://www.ncbi.nlm.nih.gov/pubmed/33888871 http://dx.doi.org/10.1038/s41417-021-00335-3

Ejemplares similares

Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation
por: Luo, Mayao, et al.
Publicado: (2023)

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
por: Luo, Mayao, et al.
Publicado: (2022)

Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer
por: Zhai, Qiliang, et al.
Publicado: (2022)

Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells
por: Shu, Minfeng, et al.
Publicado: (2011)

Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer
por: Lv, Shidong, et al.
Publicado: (2022)

Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma
por: Arseneault, Madeleine, et al.
Publicado: (2017)

MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B
por: Hong, Xuehui, et al.
Publicado: (2016)

Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion
por: Zhao, Jingyi, et al.
Publicado: (2021)

Calotropin activates YAP through downregulation of LATS1 in colorectal cancer cells
por: Zhou, Limin, et al.
Publicado: (2019)

MicroRNA-335 is downregulated in bladder cancer and inhibits cell growth, migration and invasion via targeting ROCK1
por: Wu, Deyao, et al.
Publicado: (2022)

KDM1A microenvironment, its oncogenic potential, and therapeutic significance
por: Ismail, Tayaba, et al.
Publicado: (2018)

Downregulation of YAP-dependent Nupr1 promotes tumor-repopulating cell growth in soft matrices
por: Jia, Q, et al.
Publicado: (2016)

YAP is a critical oncogene in human cholangiocarcinoma
por: Pei, Tiemin, et al.
Publicado: (2015)

The oncogenic role of NF1 in gallbladder cancer through regulation of YAP1 stability by direct interaction with YAP1
por: Zhang, Lingxiao, et al.
Publicado: (2023)

Atorvastatin potentiates the chemosensitivity of human liver cancer cells to cisplatin via downregulating YAP1
por: Guo, Liwen, et al.
Publicado: (2021)

Histone demethylase KDM4B contributes to advanced clear cell renal carcinoma and association with copy number variations and cell cycle progression
por: Tang, Heting, et al.
Publicado: (2023)

Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo
por: Almanza, Gonzalo, et al.
Publicado: (2018)

CDCA2 acts as an oncogene and induces proliferation of clear cell renal cell carcinoma cells
por: Li, Fang, et al.
Publicado: (2020)

The biology of YAP in programmed cell death
por: Cheng, Yifan, et al.
Publicado: (2022)

The oncogene Mct-1 promotes progression of hepatocellular carcinoma via enhancement of Yap-mediated cell proliferation
por: Yang, Wenjie, et al.
Publicado: (2021)

YAP in pancreatic cancer: oncogenic role and therapeutic strategy
por: Mao, Wenhao, et al.
Publicado: (2021)

An Updated Understanding of the Role of YAP in Driving Oncogenic Responses
por: Morciano, Giampaolo, et al.
Publicado: (2021)

The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma
por: Xu, Fujiang, et al.
Publicado: (2017)

Health Tract No. 335: Eyesight
Publicado: (1868)

Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis
por: Li, Yifan, et al.
Publicado: (2018)

Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma
por: Petrozza, Vincenzo, et al.
Publicado: (2015)

YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine
por: Zhou, Ling, et al.
Publicado: (2019)

YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells
por: SHENG, XIA, et al.
Publicado: (2015)

The Oncogenic Response to MiR-335 Is Associated with Cell Surface Expression of Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP) Activity
por: Rojas, Fausto, et al.
Publicado: (2015)

Circ_0064288 acts as an oncogene of hepatocellular carcinoma cells by inhibiting miR-335-5p expression and promoting ROCK1 expression
por: Nie, Yingying, et al.
Publicado: (2022)

Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation
por: Kumar, Balawant, et al.
Publicado: (2021)

Oncogenic role of ALX3 in cervical cancer cells through KDM2B-mediated histone demethylation of CDC25A
por: Qi, Jinhong, et al.
Publicado: (2021)

Functions and Targets of miR-335 in Cancer
por: Ye, Lingling, et al.
Publicado: (2021)

miR‐335 inhibited cell proliferation of lung cancer cells by target Tra2β
por: Liu, Jian, et al.
Publicado: (2017)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death
por: Liu, Jinglei, et al.
Publicado: (2019)

Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells
por: Dasari, Venkata Ramesh, et al.
Publicado: (2017)

Downregulation of YAP Activity Restricts P53 Hyperactivation to Promote Cell Survival in Confinement
por: Hemmati, Farnaz, et al.
Publicado: (2023)

YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
por: Lo Sardo, Federica, et al.
Publicado: (2018)

The oncogenic roles and clinical implications of YAP/TAZ in breast cancer
por: Luo, Juan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_llltrct5i7ojheto1bi33tll5g